Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis B vaccine (adjuvanted, adsorbed)
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Fendrix is an adjuvanted recombinant hepatitis B vaccine developed by GSK. It consists of the hepatitis B surface antigen (HBsAg) produced via recombinant DNA technology in yeast (*Saccharomyces cerevisiae*). The vaccine is formulated with the AS04C adjuvant system, which combines 3-O-desacyl-4'-monophosphoryl lipid A (MPL) and aluminium phosphate. This specific adjuvant combination is designed to accelerate and enhance the production of anti-HBs antibodies, providing a more robust and long-lasting immune response compared to standard vaccines. Fendrix is primarily indicated for active immunization against hepatitis B virus (HBV) infection in patients aged 15 years and older with renal insufficiency, including those undergoing or about to undergo haemodialysis, who typically exhibit lower seroconversion rates with conventional vaccines.
- Brand names
- Fendrix
- Other names
- HBsAg + MPL + aluminium saltsHBsAg/AS04Chepatitis B (rDNA) vaccine (adjuvanted, adsorbed)
02
Targets
HBsAg (Hepatitis B surface antigen)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on hepatitis B vaccine (adjuvanted, adsorbed).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis B vaccine (adjuvanted, adsorbed).